Recent Analyst Stock Rating News
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.Get Started for Free
Evan Wang's Stock Ratings
Guggenheim Analyst
Evan Wang is an analyst at Guggenheim. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 05/02/2025
Overall Average Return
-59.5%
Smart Score
Overall Average Return Percentile
2nd
| Buy Now | Get Alert | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 12/12/2024 | SPRB | Buy Now | Spruce Biosciences | $0.07 | — | Evan Wang8% | — | Reiterates | Neutral → Neutral | Get Alert |
| 04/05/2024 | CVAC | Buy Now | CureVac | $3.70 | — | Evan Wang8% | — | Reiterates | → Neutral | Get Alert |
| 04/05/2024 | IVVD | Buy Now | Invivyd | $0.64 | 1317.32% | Evan Wang8% | → $9 | Upgrade | Neutral → Buy | Get Alert |
| 03/22/2024 | VALN | Buy Now | Valneva | $6.53 | 160.3% | Evan Wang8% | $18 → $17 | Maintains | Buy | Get Alert |
| 03/14/2024 | SPRB | Buy Now | Spruce Biosciences | $0.07 | — | Evan Wang8% | — | Downgrade | Buy → Neutral | Get Alert |
| 02/21/2024 | SPRB | Buy Now | Spruce Biosciences | $0.07 | 14825.37% | Evan Wang8% | → $10 | Initiates | → Buy | Get Alert |
| 04/26/2023 | MRNA | Buy Now | Moderna | $28.03 | — | Evan Wang8% | — | Initiates | → Neutral | Get Alert |
